Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 86.9 kDa. The protein migrates as 90-100 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
FITC
Excitation source: 488 nm spectral line, argon-ion laser
Excitation Wavelength: 488 nm
Emission Wavelength: 535 nm
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
FITC-Labeled Human FAP, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Anti-FAP (Sibrotuzumab) Antibody,Human IgG1 at 1 μg/mL (100 μL/well) can bind FITC-Labeled Human FAP Protein, His Tag (Cat. No. FAP-HF243) with a linear range of 0.078-0.625 μg/mL (QC tested).
2e5 of anti-FAP CAR 293 cells were stained with 100 μL of 3 μg/mL of FITC-Labeled Human FAP, His Tag (Cat. No. FAP-HF243) and negative control protein respectively, FITC signals was used to evaluate the binding activity (QC tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Talabostat | VbP; PT-100; BXCL-701 | Phase 2 Clinical | Point Therapeutics | Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Melanoma; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasms, Germ Cell and Embryonal; Neoplasm Metastasis; Carcinoma, Pancreatic Ductal; Carcinoma, Small Cell; Lung Neoplasms; Leukemia, Myeloid, Acute; Prostatic Neoplasms; Kidney Neoplasms; Sarcoma; Neuroblastoma; Neuroendocrine Tumors; Central Nervous System Neoplasms; Pancreatic Neoplasms; Myelodysplastic Syndromes; Skin Neoplasms; Ovarian Neoplasms; Liver Neoplasms; Solid tumours | Details |
68Ga-TCR-FAPI | 68Ga-TCR-FAPI | Phase 2 Clinical | Tumor Research Institute Chinese Academy Of Medical Sciences | Neoplasms; Medullary thyroid cancer (MTC) | Details |
NTI-1309 | NTI-1309; LNTH-1363S; 64Cu-LNTH-1363S | Phase 2 Clinical | Noria Therapeutics Inc | Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Sarcoma; Colorectal Neoplasms | Details |
177Lu-EB-FAPI | 177Lu-EB-FAPI | Phase 2 Clinical | Zhejiang University | Pancreatic Neoplasms; Cholangiocarcinoma; Carcinoma, Pancreatic Ductal | Details |
177Lu-DOTA-EB-FAPI | Phase 2 Clinical | The First Affiliated Hospital Of Xiamen University | Solid tumours; Adenocarcinoma, Follicular; Thyroid Neoplasms; Thyroid Cancer, Papillary | Details | |
[18F]FAPI-74 | FAPI-74; [18F]FAPI-74; Fluor-18-FAPI-74; F-18]FAPI-74 | Phase 2 Clinical | University Of Heidelberg | Biliary Tract Neoplasms; Ovarian Neoplasms; Dermatomyositis; Stomach Neoplasms; Pheochromocytoma; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular | Details |
[18F]fibronstatin | 18F-LNC1005 | Phase 2 Clinical | Shanghai Lannacheng Biotechnology Co Ltd | Solid tumours; Diagnostic agents | Details |
68Ga-FAP-2286 | 68-Ga-FAP-2286; 68Ga-FAP-2286 | Phase 2 Clinical | 3B Pharmaceuticals GmbH | Solid tumours; Neoplasm Metastasis | Details |
68Ga-FAPI-46 | [68Ga]FAPI-46; 68Ga-FAPI-46 | Phase 2 Clinical | Karolinska University Hospital | Neoplasms; Carcinoma, Hepatocellular; Alveolitis, Extrinsic Allergic; Pneumoconiosis; Carcinoma, Pancreatic Ductal; Bile Duct Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Pulmonary Fibrosis; Lung Diseases, Interstitial; Carcinoma, Ovarian Epithelial; Adenomatous Polyposis Coli; Pancreatic Neoplasms; Pneumonia; Stomach Neoplasms; Esophageal Neoplasms; Metabolic Dysfunction-Associated Steatotic Liver Disease; Radiation Pneumonitis; Idiopathic Interstitial Pneumonias; Ovarian Neoplasms | Details |
177Lu-FAP-2286 | 177Lu-FAP-2286 | Phase 2 Clinical | 3B Pharmaceuticals GmbH | Solid tumours | Details |
RO-7122290 | RO-7122290; RG-7827 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Colorectal Neoplasms | Details |
NG-641 | EnAd-FAP-BiTE; EnAd-FAP-Tac; NG-641; NG-aFAP | Phase 1 Clinical | Akamis Bio Ltd, University Of Oxford | Squamous Cell Carcinoma of Head and Neck; Neoplasms, Glandular and Epithelial; Neoplasm Metastasis | Details |
Simlukafusp alfa | FAP-IL2v; RG-7461; aFAP-IL2v; RO-6874281; FAP-IL2v FP | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Head and Neck Neoplasms; Solid tumours; Esophageal Neoplasms; Carcinoma, Renal Cell; Breast Neoplasms; Uterine Cervical Neoplasms; Melanoma | Details |
68Ga-PNT-6555 | Phase 1 Clinical | Point Biopharma Inc | Solid tumours; Esophageal Neoplasms; Sarcoma; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Melanoma | Details | |
68Ga-FAPI-XT-117 | Phase 1 Clinical | Beijing Xiantong International Technology Co Ltd | Solid tumours | Details | |
64Cu-FAPI-XT117 | Phase 1 Clinical | Beijing Xiantong International Technology Co Ltd | Solid tumours | Details | |
OMTX-705 | OMTX-705 | Phase 1 Clinical | Oncomatryx Biopharma Sl | Solid tumours | Details |
MP-0310 | MP-0310; AMG-506 | Phase 1 Clinical | Molecular Partners Ag, Amgen Inc | Solid tumours | Details |
68Ga-NI-FAPI | 68Ga-NI-FAPI | Phase 1 Clinical | First Affiliated Hospital Of Fujian Medical University | Neoplasms | Details |
177Lu-FAPI-RGD | 177Lu-FAPI-RGD | Phase 1 Clinical | Peking Union Medical College Hospital | Neoplasms | Details |
177Lu-JH04 | 177Lu-JH04 | Phase 1 Clinical | First Affiliated Hospital Of Fujian Medical University | Neoplasms | Details |
Lutetium [177Lu]-FAP-75 | Lutetium [177Lu]-FAP-75 | Phase 1 Clinical | Fudan University | Solid tumours | Details |
68Ga-JH04 | 68Ga-JH04; JH-04 | Phase 1 Clinical | Bivision Pharmaceuticals Inc | Neoplasms | Details |
68Ga-FAPI-JH04 | 68Ga-FAPI-JH04 | Phase 1 Clinical | First Affiliated Hospital Of Fujian Medical University | Neoplasms | Details |
68Ga-PSFA | 68Ga-PSFA | Phase 1 Clinical | First Affiliated Hospital Of Chongqing Medical University | Adenomatous Polyposis Coli | Details |
68 Ga-OncoFAP-DOTAGA | 68 Ga-OncoFAP | Phase 1 Clinical | Blue Earth Diagnostics, Philochem | Solid tumours | Details |
AAA-614 | AAA-614; FAP-2286 | Phase 1 Clinical | Novartis Ag | Solid tumours | Details |
18F-AlF-FAPi-04 | 18F-AlF-FAPi-04 | Phase 1 Clinical | Affiliated Hospital Of North Sichuan Medical College | Solid tumours | Details |
177Lu-EB-FAPI(Peking Union Medical College Hospital) | 177Lu-EB-FAPI(Peking Union Medical College Hospital) | Phase 1 Clinical | Peking Union Medical College Hospital | Neoplasm Metastasis | Details |
68Ga-FAPI(Peking Union Medical College Hospital) | 68Ga-FAPI(Peking Union Medical College Hospital) | Phase 1 Clinical | Peking Union Medical College Hospital | Neoplasm Metastasis | Details |
[177Lu]Lu-XT117 | [177Lu]Lu-XT117 | Phase 1 Clinical | Beijing Xiantong International Technology Co Ltd | Solid tumours | Details |
RTX-1363-S | RTX-1363S; RTX-1363-S | Phase 1 Clinical | Ratio Therapeutics Inc | Stomach Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Lung Neoplasms | Details |
68Ga/64Cu-FAPI-XT117 | 68Ga/64Cu-FAPI-XT117 | Phase 1 Clinical | Beijing Xiantong International Technology Co Ltd | Solid tumours | Details |
177Lu-LNC1004 | 177Lu-LNC1004; 177Lu-LNC-1004 | Phase 1 Clinical | Shanghai Lannacheng Biotechnology Co Ltd | Solid tumours | Details |
68Ga-FAPI-RGD | 68Ga-FAPI-RGD; 68Ga-LNC-1007 | Phase 1 Clinical | Peking Union Medical College Hospital, Fujian Medical University | Carcinoma, Renal Cell; Neoplasms; Lung Neoplasms | Details |
SHR-7367 | SHR7367; SHR-7367 | Phase 1 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
177Lu-PNT6555(Point Biopharma) | PNT-6555 | Phase 1 Clinical | Point Biopharma Inc | Skin Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Sarcoma; Cholangiocarcinoma; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal | Details |
RO-7300490 | RO-7300490; RG-6189; FAP-CD40; FAP-huCD40 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours | Details |
anti-BCMA/NKG2DL/FAP TCR T-cell therapy (Guangdong VitaLife) | Clinical | Multiple Myeloma | Details | ||
177Lu-BRP-010 | BRP-010; 177Lu-BRP-010 | Clinical | BoomRay Pharmaceuticals Co Ltd | Solid tumours | Details |
68Ga-BRP-010 | BRP-010; 68Ga-BRP-010 | Clinical | BoomRay Pharmaceuticals Co Ltd | Solid tumours | Details |
[90Y] YFAPI-46 | Clinical | German Cancer Consortium (Dktk), University of Duisburg-Essen | Solid tumours | Details | |
3BP-3940 | 3BP-3940 | Clinical | Johannes Gutenberg University Of Mainz, 3B Pharmaceuticals GmbH | Neoplasms | Details |
This web search service is supported by Google Inc.